Table 4 Clinical characteristics of the 7 infants with CMV infection
From: Prevention of human milk-acquired cytomegalovirus infection in very-low-birth-weight infants
No. | GA (weeks), BW (gram) | Sex | Number of transfusions (PRBC / PC / FFP) | Study group | Age at diagnosis (PCA) | CMV-positive specimen | Average HM intake (mL/day) | Symptom | Duration of gancyclovir treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 25 + 2, 720 | F | 17 / 0 / 0 | FT + LP | 28 (29 + 2) | Blood, urine, BAL, CSF | 71 | Lung | 3 weeks | Survived |
2 | 28 + 6, 1210 | M | 6 / 0 / 0 | FT + HP | 28 (32 + 6) | Urine | 89 | None | 2 weeks | Survived |
3 | 27 + 2, 1040 | F | 25 / 23 / 0 | FT + LP | 29 (31 + 3) | Blood, urine, sputum | 11 | Lung, SLS (PLT↓, AST/ALT↑) | 3 weeks | Died |
4 | 26 + 6, 1080 | F | 5 / 0 / 6 | FT | 83 (39 + 2) | Urine | 153 | None | N/A | Survived |
5 | 24 + 0, 630 | M | 27 / 14 / 2 | FT + LP | 56 (32 + 0) | Urine | 104 | None | N/A | Survived |
6 | 33 + 4, 1420 | F | 0 / 0 / 0 | FT + LP | 28 (37 + 4) | Urine | 41 | None | N/A | Survived |
7 | 32 + 6, 990 | F | 0 / 0 / 0 | FT | 56 (40 + 6) | Urine | 94 | None | N/A | Survived |